Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Clinical Trials & Observations

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

DOI: https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura

Erika Tarasco, Lukas Bütikofer, Kenneth D. Friedman, James N George, Ingrid V Hrachovinova, Paul Knöbl, Masanori Matsumoto, Anne Sophie von Krogh, Isabella Aebi-Huber, Zuzana Cermakova, Magdalena Górska-Kosicka, Katarzyna A. Jalowiec, Carlo R. Largiadèr, Zoltan Prohaszka, György Sinkovits, Jerzy Windyga, Bernhard Lämmle, Johanna A Kremer Hovinga

Blood blood.2020009801.

DOI: https://doi.org/10.1182/blood.2020009801

Published: 2021

Includes: Supplemental data

Journal Articles

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Cedric Hermans, MDMRCP,PhD, Claude Négrier, Pål A Holme, Carmen Escuriola, Ana R Cid, Nataliya Kemenyash, MSc, Jaco Botha, Viridiana Cano-Garcia, Jerzy Windyga

Blood (2020) 136 (Supplement 1): 23–24.

DOI: https://doi.org/10.1182/blood-2020-139298

Published: 2020

Journal Articles

Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data

Magdalena Katarzyna Letowska, Krystyna Zawilska, MD PhD, Anna Klukowska, MD PhD, Krzysztof Chojnowski, MD PhD, Joanna Zdziarska, MD PhD, Ewa Stefanska-Windyga, MD PhD, Jerzy Windyga

Blood (2019) 134 (Supplement_1): 4942.

DOI: https://doi.org/10.1182/blood-2019-122422

Published: 2019

Journal Articles

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola

Blood (2019) 134 (Supplement_1): 2418.

DOI: https://doi.org/10.1182/blood-2019-124324

Published: 2019

Journal Articles

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Jerzy Windyga, Oleksandra Stasyshyn, MD PhD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD

Blood (2018) 132 (Supplement 1): 1197.

DOI: https://doi.org/10.1182/blood-2018-99-111295

Published: 2018

Journal Articles

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Victor Jimenez-Yuste, Midori Shima, MD PhD, Ido Paz-Priel, Aric Parnes, Michaela Lehle, Adam Giermasz, Avrita Campinha-Bacote, Markus Niggli, Jerzy Windyga, Sammy Chebon, Peter Trask, Johnny Mahlangu, Steven Pipe, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 1187.

DOI: https://doi.org/10.1182/blood-2018-99-118132

Published: 2018

Journal Articles

Explore: A Prospective, Multinational Natural History Study of Patients with Acute Hepatic Porphyrias (AHP) with Recurrent Attacks

Blood (2017) 130 (Supplement 1): 2211.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2211.2211

Published: 2017

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

Journal Articles

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Michael U. Callaghan, Claude Negrier, Guy Young, Liane Khoo, Johnny Mahlangu, Jerzy Windyga, Johannes Oldenburg, Jin Xu, Olivier Catalani, Elina Asikanius, Joanne I. Adamkewicz, Midori Shima, MDPhD

Blood (2017) 130 (Supplement 1): 3668.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3668.3668

Published: 2017

Journal Articles

Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A

Hermann Eichler, MD, Pantep Angchaisuksiri, MD, Kaan Kavakli, MD, Paul Knöbl, MD PhD, Jerzy Windyga, Victor Jimenez-Yuste, Ute Friedrich, PhD, Philip Delff Andersen, Pratima Chowdary

Blood (2017) 130 (Supplement 1): 3672.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3672.3672

Published: 2017

Journal Articles

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Clinical Trials & Observations

Marie Scully, Paul Knöbl, Karim Kentouche, Lawrence Rice, Jerzy Windyga, Reinhard Schneppenheim, Johanna A. Kremer Hovinga, Michiko Kajiwara, Yoshihiro Fujimura, Caterina Maggiore, Jennifer Doralt, Christopher Hibbard, Leah Martell, Bruce Ewenstein

Blood (2017) 130 (19): 2055–2063.

DOI: https://doi.org/10.1182/blood-2017-06-788026

Published: 2017

Includes: Supplemental data

Journal Articles

Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Nirjhar Chatterjee, MD

Blood (2016) 128 (22): 4978.

DOI: https://doi.org/10.1182/blood.V128.22.4978.4978

Published: 2016

Journal Articles

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Marie Scully, Paul Knoebl, MD, Karim Kentouche, Lawrence Rice, MD, Jerzy Windyga, MD, Reinhard Schneppenheim, Johanna A Kremer Hovinga, MD PhD, Michiko Kajiwara, Caterina Maggiore, Jennifer Doralt, Leah Martell, Bruce M. Ewenstein

Blood (2016) 128 (22): 135.

DOI: https://doi.org/10.1182/blood.V128.22.135.135

Published: 2016

Journal Articles

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Yesim G. Dargaud, MDPhD, Robert Klamroth, Luminita Rusen, MD, Jerzy Windyga, MD, Johann Bichler, PhD, Sigurd Knaub, Claude Negrier, MD

Blood (2016) 128 (22): 1410.

DOI: https://doi.org/10.1182/blood.V128.22.1410.1410

Published: 2016

Journal Articles

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Vasily Mamonov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 2585.

DOI: https://doi.org/10.1182/blood.V128.22.2585.2585

Published: 2016

Journal Articles

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ana Rosa Cid, MD, Carmen Escuriola, MD, Cedric R. Hermans, MD PhD MRCP, Pal André Holme, PhD MD, Claude Negrier, MD, Savita Rangarajan, Angiola Rocino, Jerzy Windyga, MD, Alessandro Gringeri, MD MSc, Roberto Crea, DVM, MSc

Blood (2016) 128 (22): 5038.

DOI: https://doi.org/10.1182/blood.V128.22.5038.5038

Published: 2016

Journal Articles

Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies

Roshni Kulkarni, Amy D Shapiro, MD, Jerzy Windyga, Margaret V Ragni, K John Pasi, Margareth Castro Ozelo, MD PhD, Elisa Tsao, Baisong Mei

Blood (2015) 126 (23): 2307.

DOI: https://doi.org/10.1182/blood.V126.23.2307.2307

Published: 2015

Journal Articles

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Clinical Trials & Observations

Joan C. Gill, Giancarlo Castaman, Jerzy Windyga, Peter Kouides, Margaret Ragni, Frank W. G. Leebeek, Ortrun Obermann-Slupetzky, Miranda Chapman, Sandor Fritsch, Borislava G. Pavlova, Isabella Presch, Bruce Ewenstein

Blood (2015) 126 (17): 2038–2046.

DOI: https://doi.org/10.1182/blood-2015-02-629873

Published: 2015

Journal Articles

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Christoph J. Hofbauer, Shawn F. J. Whelan, Maria Hirschler, Peter Allacher, Frank M. Horling, John-Philip Lawo, Johannes Oldenburg, Andreas Tiede, Christoph Male, Jerzy Windyga, Andreas Greinacher, Paul N. Knöbl, Gerald Schrenk, Jadranka Koehn, Friedrich Scheiflinger, Birgit M. Reipert

Blood (2015) 125 (7): 1180–1188.

DOI: https://doi.org/10.1182/blood-2014-09-598268

Published: 2015

Includes: Supplemental data

NARROW

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Explore: A Prospective, Multinational Natural History Study of Patients with Acute Hepatic Porphyrias (AHP) with Recurrent Attacks

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only